ArticleAmerican journal of translational research2025
Value of Q-switched 755-nm alexandrite laser combined with topical tranexamic acid in the treatment of melasma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the clinical value of Q-switched 755-nm alexandrite laser combined with topical tranexamic acid in treating melasma.
methodsA total of 121 melasma patients treated at AIST Medical Cosmetology Hospital from July 2022 to January 2024 were retrospectively included. They were divided into two groups: the Laser Treatment Group (LTG, n=61), receiving Q-switched 755-nm alexandrite laser combined with topical tranexamic acid, and the Control Treatment Group (CTG, n=60), receiving only topical tranexamic acid. Clinical efficacy, skin scores before and after treatment, laboratory indicators, melanin index, dermoscopic scores for pigmentation and vascular components, dermoscopic typing improvement, adverse reactions, and recurrence rates were compared.
resultsThe treatment efficacy rate was 93.44% in the LTG, significantly higher than 81.67% in the CTG (P<0.05). After treatment, the LTG showed significantly lower Melasma Area and Severity Index (MASI) scores, skin lesion color, and area scores compared to the CTG (all P<0.05). No significant differences were found in malondialdehyde (MDA) and superoxide dismutase (SOD) levels (both P>0.05). The LTG had a lower melanin index and dermoscopic scores for telangiectasia and perifollicular pigmentation than the CTG (all P<0.05). The incidence of adverse reactions in the LTG was 11.48%, significantly lower than 40.00% in the CTG (P<0.05). The LTG also had a lower recurrence rate of 1.64% at 6-month follow-up, compared to 10.00% in the CTG (P<0.05).
conclusionQ-switched 755-nm alexandrite laser combined with topical tranexamic acid is highly effective in treating melasma, improving clinical symptoms, reducing oxidative stress and inflammation, and yielding better results in vascular proliferation and pigmentation. The treatment also demonstrated a low recurrence rate, suggesting its potential for broader use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.